A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG) Meeting Abstract
| Authors: | Desjardins, A.; Chandramohan, V.; Landi, D. B.; Johnson, M. O.; Khasraw, M.; Peters, K. B.; Low, J.; Herndon, J. E.; Threatt, S.; Bullock, C. A.; Lipp, E. S.; Sampson, J. H.; Friedman, A. H.; Friedman, H. S.; Ashley, D. M.; Knorr, D.; Bigner, D. D. |
| Abstract Title: | A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302754 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.e14015 |
| Notes: | Meeting Abstract: e14015 -- This meeting was also held virtually -- Source: Wos |
